Evidence map›Paper›PMID 37817020›Full record

ReviewMolecular biology reports2023

Green synthesis of nano-based drug delivery systems developed for hepatocellular carcinoma treatment: a review.

Doaa S R Khafaga, Ahmed M El-Khawaga, Rehab Abd Elfattah Mohammed, Heba K Abdelhakim

Erratum issuedOpen access · hybridAbstract readReview
In one paragraph

Review in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Doaa S R KhafagaDepartment of Basic Medical Sciences, Faculty of Medicine, Galala University, Suez, 43511, Egypt. doaa.rashwan@gu.edu.eg.ORCID http://orcid.org/0000-0002-0576-0100
Ahmed M El-KhawagaDepartment of Basic Medical Sciences, Faculty of Medicine, Galala University, Suez, 43511, Egypt. Ahmed.Elkhawaga@gu.edu.eg.ORCID http://orcid.org/0000-0002-1944-0167
Rehab Abd Elfattah MohammedFaculty of medicine for girls, Internal medicine Al Azher university, Cairo, Egypt.
Heba K AbdelhakimBiochemistry Division, Faculty of Science, Cairo University, Giza, 12613, Egypt.
Suez University · EGAl-Azhar University · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review presents an overview of one of the effective strategies for improving the anticancer impact of many drugs including sorafenib using a drug delivery system by employing nanoparticles that is produced through a biological system. The biological process has a lot of benefits, including being inexpensive and safe for the environment. Sorafenib is one of a multi-kinase inhibitor that inhibits molecularly targeted kinases. Because of its poor pharmacokinetic characteristics, such as fast elimination and limited water solubility, the bioavailability of Sorafenib is extremely low. More intelligent nano formulations of sorafenib have been developed to boost both the drug's target ability and bioavailability. Researchers in a wide variety of sectors, including nanomedicine, have recently been interested in the topic of nanotechnology. It is possible for the body to develop resistance to widely used drugs available for treatment of liver cancer, including sorafenib. As a result, our goal of this research is to highlight the efficacy of nanomedicine-based drug delivery system to enhance drug's cancer-fighting properties. Because of their magnetic properties, certain nanoparticle materials can be employed as a carrier for the medicine to the exact place where the cancer is located. This can lower the amount of the drug that is administered with no impact on the normal cells.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsNanoparticlesDrug Delivery SystemsHumansNanoparticle Drug Delivery SystemSorafenibAntineoplastic AgentsNanoparticle Drug Delivery SystemSorafenibCancerHepatocellular carcinomaNanoparticlesSorafenib

Identifiers

PMID37817020
PMCPMC10676320
OpenAlexW4387494068

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.